Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
In this research, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel (KLA-5-FU/PTX Lps) were developed, and their antitumor activity against triple-negative breast cancer (TNBC) was evaluated. KLA-5-FU/PTX Lps were prepared using the thin-film dispersion method, and their in vitro a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/7/881 |
| _version_ | 1797433200297902080 |
|---|---|
| author | Tianyu Chen Hui Chen Yichun Jiang Qi Yan Shuling Zheng Min Wu |
| author_facet | Tianyu Chen Hui Chen Yichun Jiang Qi Yan Shuling Zheng Min Wu |
| author_sort | Tianyu Chen |
| collection | DOAJ |
| description | In this research, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel (KLA-5-FU/PTX Lps) were developed, and their antitumor activity against triple-negative breast cancer (TNBC) was evaluated. KLA-5-FU/PTX Lps were prepared using the thin-film dispersion method, and their in vitro anticancer efficacy was assessed in human breast cancer cells (MDA-MB-231). An MDA-MB-231 tumor-bearing mouse model was also established to evaluate their antitumor efficacy in vivo. KLA-5-FU/PTX Lps showed enhanced cytotoxicity against MDA-MB-231 cells, improved drug delivery to mitochondria, and induced mitochondria-mediated apoptosis. The modified liposomes also showed favorable antitumor activity in vivo due to their strong ability to target tumors and mitochondria. The liposomes showed no obvious systemic toxicity. Our results suggest that KLA-5-FU/PTX Lps are a promising system with which to target the delivery of antitumor drugs to mitochondria as a treatment for TNBC. |
| first_indexed | 2024-03-09T10:13:39Z |
| format | Article |
| id | doaj.art-9e28965e97a342cf83f0bae2b3d65caa |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T10:13:39Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-9e28965e97a342cf83f0bae2b3d65caa2023-12-01T22:33:44ZengMDPI AGPharmaceuticals1424-82472022-07-0115788110.3390/ph15070881Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer TreatmentTianyu Chen0Hui Chen1Yichun Jiang2Qi Yan3Shuling Zheng4Min Wu5School of Pharmacy, Chengdu Medical College, No. 783 Xindu Avenue, Xindu District, Chengdu 610500, ChinaSchool of Healthcare Technology, Chengdu Neusoft University, No. 1 Neusoft Avenue, Dujiangyan District, Chengdu 611830, ChinaSchool of Pharmacy, Chengdu Medical College, No. 783 Xindu Avenue, Xindu District, Chengdu 610500, ChinaSchool of Pharmacy, Chengdu Medical College, No. 783 Xindu Avenue, Xindu District, Chengdu 610500, ChinaSchool of Pharmacy, Chengdu Medical College, No. 783 Xindu Avenue, Xindu District, Chengdu 610500, ChinaSchool of Pharmacy, Chengdu Medical College, No. 783 Xindu Avenue, Xindu District, Chengdu 610500, ChinaIn this research, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel (KLA-5-FU/PTX Lps) were developed, and their antitumor activity against triple-negative breast cancer (TNBC) was evaluated. KLA-5-FU/PTX Lps were prepared using the thin-film dispersion method, and their in vitro anticancer efficacy was assessed in human breast cancer cells (MDA-MB-231). An MDA-MB-231 tumor-bearing mouse model was also established to evaluate their antitumor efficacy in vivo. KLA-5-FU/PTX Lps showed enhanced cytotoxicity against MDA-MB-231 cells, improved drug delivery to mitochondria, and induced mitochondria-mediated apoptosis. The modified liposomes also showed favorable antitumor activity in vivo due to their strong ability to target tumors and mitochondria. The liposomes showed no obvious systemic toxicity. Our results suggest that KLA-5-FU/PTX Lps are a promising system with which to target the delivery of antitumor drugs to mitochondria as a treatment for TNBC.https://www.mdpi.com/1424-8247/15/7/8815-fluorouracilpaclitaxelliposomesmitochondrial targetingTNBC |
| spellingShingle | Tianyu Chen Hui Chen Yichun Jiang Qi Yan Shuling Zheng Min Wu Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment Pharmaceuticals 5-fluorouracil paclitaxel liposomes mitochondrial targeting TNBC |
| title | Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment |
| title_full | Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment |
| title_fullStr | Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment |
| title_full_unstemmed | Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment |
| title_short | Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment |
| title_sort | co delivery of 5 fluorouracil and paclitaxel in mitochondria targeted kla modified liposomes to improve triple negative breast cancer treatment |
| topic | 5-fluorouracil paclitaxel liposomes mitochondrial targeting TNBC |
| url | https://www.mdpi.com/1424-8247/15/7/881 |
| work_keys_str_mv | AT tianyuchen codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment AT huichen codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment AT yichunjiang codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment AT qiyan codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment AT shulingzheng codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment AT minwu codeliveryof5fluorouracilandpaclitaxelinmitochondriatargetedklamodifiedliposomestoimprovetriplenegativebreastcancertreatment |